COVID-19 Vaccine for Respiratory Tract Infections

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Arizona, Tucson, AZ
Respiratory Tract Infections+3 More
COVID-19 Vaccine - Biological
Eligibility
18 - 65
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether exercise can improve the immune system against viruses.

See full description

Eligible Conditions

  • Respiratory Tract Infections
  • COVID-19 Respiratory Infection
  • Flu caused by Influenza

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Respiratory Tract Infections

Study Objectives

This trial is evaluating whether COVID-19 Vaccine will improve 5 primary outcomes in patients with Respiratory Tract Infections. Measurement will happen over the course of 1 year.

1 year
Determine IFN-γ concentration after whole blood stimulation with SARS-CoV-2 peptides
Determine IFN-γ spot forming cells after stimulation with SARS-CoV-2 peptides
Determine SARS-CoV-2 T-cell phenotype
Determine SARS-CoV-2 T-cells TCR-β diversity
Expand SARS-CoV-2 specific T-cells

Trial Safety

Safety Progress

1 of 3

Other trials for Respiratory Tract Infections

Trial Design

1 Treatment Group

Vaccine
1 of 1
Experimental Treatment

This trial requires 30 total participants across 1 different treatment group

This trial involves a single treatment. COVID-19 Vaccine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Vaccine
Biological
Participants who elect to receive the vaccine

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 1 year for reporting.

Closest Location

University of Arizona - Tucson, AZ

Eligibility Criteria

This trial is for patients born any sex between 18 and 65 years old. There is one eligibility criterion to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
'low risk' for submaximal exercise testing in accordance with the risk stratification guidelines published by the American Heart Association and the American College of Sports Medicine (AHA/ACSM criteria). We will also determine the participant's current vaccine status (influenza, chickenpox, etc) and COVID-19 infection status. Infection status will be determined via self-report and Spike protein IgG titer levels We will simply ask the participant (self-report) when they received the vaccine and, if they know, which vaccine they received (e.g. Moderna or Pfizer for the COVID-19 vaccine). However, only participants that have been vaccinated (1-3 weeks after second dose) or tested positive (greater than 2-months symptom free) for COVID-19 by either PCR, antigen, or antibody testing will be eligible for Aim 2. After providing informed consent, all participants will undergo a comprehensive screening procedure to ensure that AHA/ACSM criteria are met.

Patient Q&A Section

Does respiratory tract infections run in families?

"The present study supports the occurrence of a major component of heritability for the familial aggregation of respiratory infections, although the magnitude of such a familial component remains unclear." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of respiratory tract infections?

"A total of 25% of HMPE patients had at least one respiratory tract infection. We speculate that the number may be higher with a higher HMPE severity." - Anonymous Online Contributor

Unverified Answer

What causes respiratory tract infections?

"Atypical pneumonia, or community-acquired pneumonia, is an important cause of acute respiratory illness in the community and a common reason for hospital admission. The vast majority of ambulatory cases of pneumonia are not caused by atypical pathogens. However, the majority of cases are prevented by appropriate antibiotic therapy." - Anonymous Online Contributor

Unverified Answer

Can respiratory tract infections be cured?

"Results from a recent paper does not support the hypothesis that patients with MDR-TB can be cured to a degree comparable to non-resistant, smear-negative patients. Patients with advanced TB should be provided prompt treatment for active symptoms, which can help to prevent further transmission." - Anonymous Online Contributor

Unverified Answer

What are the signs of respiratory tract infections?

"Respiratory infections are common in children and may be associated with a number of signs and symptoms. The most common are cough (97%) and upper airways obstruction. Children with unexplained fevers and lower respiratory tract signs and symptoms merit special consideration." - Anonymous Online Contributor

Unverified Answer

How many people get respiratory tract infections a year in the United States?

"Approximately 16 million people get respiratory tract infections a year in the United States. People over age 5 and people with underlying diseases tend to have increased rates of infections. Approximately 5 to 10% of respiratory tract infections are caused by strains of bacteria for which selective antibiotic treatment is available. The potential for antibiotic resistance is present if antibiotics are prescribed indiscriminately. There is a high rate of utilization of antibiotics by ambulatory settings, including physicians' office visits, in the United States when they are not medically indicated." - Anonymous Online Contributor

Unverified Answer

What is respiratory tract infections?

"RTI cause more or less 25% of hospitalizations in children under the age of 5 years. The main diagnostic factors are the need for mechanical ventilation, respiratory rate above 40+/min and white cell count over 10×10. The treatment consists primarily and not necessarily on antibiotics; prophylaxis of RTIs are not used mainly." - Anonymous Online Contributor

Unverified Answer

What are common treatments for respiratory tract infections?

"Respiratory infections are common in healthcare centres, and most individuals receive some type of treatment for them. When antibiotics are prescribed, they usually are to treat presumed bacterial infections. Most treatments for a respiratory infection also have other systemic effects (e.g., sedation or nausea). Respiratory tract infections are commonly treated with antibiotics of the beta-lactam or macrolide class. The treatments for a viral infection tend to be less active, although steroids or antivirals (e.g., zanamivir) can be of utility if this is the problem." - Anonymous Online Contributor

Unverified Answer

Is covid-19 vaccine safe for people?

"The SARS vaccination trial demonstrated that the vaccine is safe and immunogenic in adults and will protect against infection with SARS coronavirus. SARS-CoV-2 is a similar viral pathogen that can cause disease similar to SARS. The SARS-CoV-2 virus is highly infectious; the virus is transmitted from person to person. As a result, people should consider staying at home, staying vigilant and wearing face masks if there is an outbreak in their community, as is currently recommended by the US CDC." - Anonymous Online Contributor

Unverified Answer

What is covid-19 vaccine?

"The data we reviewed are limited but may shed some light on potential immunogenicity of vaccine formulations against COVID-19, and the relevance of antigenically diverse viruses. There is an urgent need to fund prospective, randomized control studies to determine whether a standardized dose vaccine against COVID-19 will confer protection to recipients against disease in a susceptible population." - Anonymous Online Contributor

Unverified Answer

How does covid-19 vaccine work?

"The CV-19 vaccine in the current Phase 1b trials appears to be well tolerated by all participants and produces high rates of protection against CV-19 infection. The CV-19 vaccine shows a promising safety profile in CV-19 disease and therefore is a promising vaccine candidate for further evaluation. Clinical Trials Registry Number: NCT02277789." - Anonymous Online Contributor

Unverified Answer

Is covid-19 vaccine typically used in combination with any other treatments?

"Patients with SARS or MERS virus infection were typically prescribed an antiviral treatment in addition to vaccination during their initial medical management. However, no studies were found that demonstrated the use of a vaccine in addition to another treatment for an SARS or MERS infection. However, further study on vaccine use for treatment in addition to other therapies may be beneficial." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Respiratory Tract Infections by sharing your contact details with the study coordinator.